Avadel Pharmaceuticals PLCNASDAQ:AVDL
- LAST PRICE14.9200
- TODAY'S CHANGE (%)0.0600 (0.4038%)
- Bid / Lots14.9100/ 7
- Ask / Lots14.9300/ 7
- Open / Previous Close14.8300 / 14.8600
- Day Range
- 52 Week Range
- Volume256,241
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AVDL |
|---|---|---|
| 09:32 ET | 6683 | 14.73 |
| 09:33 ET | 700 | 14.67 |
| 09:35 ET | 300 | 14.75 |
| 09:37 ET | 100 | 14.73 |
| 09:39 ET | 100 | 14.76 |
| 09:42 ET | 100 | 14.79 |
| 09:44 ET | 900 | 14.75 |
| 09:46 ET | 1091 | 14.745 |
| 09:48 ET | 800 | 14.76 |
| 09:50 ET | 200 | 14.74 |
| 09:51 ET | 100 | 14.73 |
| 09:53 ET | 8967 | 14.73 |
| 09:55 ET | 900 | 14.77 |
| 09:57 ET | 1150 | 14.725 |
| 10:00 ET | 6814 | 14.6153 |
| 10:02 ET | 525 | 14.645 |
| 10:04 ET | 1955 | 14.578 |
| 10:06 ET | 1850 | 14.66 |
| 10:08 ET | 1501 | 14.58 |
| 10:09 ET | 900 | 14.4942 |
| 10:11 ET | 1263 | 14.535 |
| 10:13 ET | 1291 | 14.53 |
| 10:15 ET | 500 | 14.525 |
| 10:18 ET | 11546 | 14.445 |
| 10:20 ET | 1500 | 14.53 |
| 10:22 ET | 300 | 14.535 |
| 10:24 ET | 2306 | 14.595 |
| 10:26 ET | 12000 | 14.66 |
| 10:27 ET | 2200 | 14.66 |
| 10:29 ET | 1659 | 14.61 |
| 10:31 ET | 833 | 14.615 |
| 10:33 ET | 893 | 14.615 |
| 10:36 ET | 621 | 14.615 |
| 10:38 ET | 200 | 14.63 |
| 10:40 ET | 2553 | 14.645 |
| 10:42 ET | 1686 | 14.72 |
| 10:44 ET | 501 | 14.76 |
| 10:45 ET | 100 | 14.745 |
| 10:47 ET | 500 | 14.77 |
| 10:49 ET | 200 | 14.73 |
| 10:51 ET | 835 | 14.725 |
| 10:54 ET | 4375 | 14.78 |
| 10:56 ET | 550 | 14.8 |
| 10:58 ET | 300 | 14.78 |
| 11:00 ET | 717 | 14.8 |
| 11:02 ET | 732 | 14.82 |
| 11:03 ET | 300 | 14.82 |
| 11:05 ET | 10916 | 14.87 |
| 11:07 ET | 2731 | 14.965 |
| 11:09 ET | 1408 | 14.98 |
| 11:12 ET | 4200 | 14.93 |
| 11:14 ET | 1905 | 14.89 |
| 11:16 ET | 662 | 14.93 |
| 11:18 ET | 1007 | 14.89 |
| 11:20 ET | 707 | 14.89 |
| 11:21 ET | 100 | 14.89 |
| 11:23 ET | 200 | 14.89 |
| 11:25 ET | 3792 | 14.915 |
| 11:27 ET | 2147 | 14.93 |
| 11:30 ET | 800 | 14.92 |
| 11:32 ET | 5685 | 14.895 |
| 11:34 ET | 1950 | 14.94 |
| 11:36 ET | 2225 | 14.9 |
| 11:38 ET | 1515 | 14.945 |
| 11:39 ET | 200 | 14.95 |
| 11:41 ET | 820 | 14.97 |
| 11:43 ET | 822 | 14.97 |
| 11:45 ET | 1400 | 14.985 |
| 11:48 ET | 1350 | 14.96 |
| 11:50 ET | 680 | 14.925 |
| 11:52 ET | 8402 | 14.995 |
| 11:54 ET | 2830 | 14.945 |
| 11:56 ET | 1300 | 14.93 |
| 11:57 ET | 700 | 14.905 |
| 11:59 ET | 400 | 14.905 |
| 12:01 ET | 1600 | 14.94 |
| 12:03 ET | 200 | 14.92 |
| 12:06 ET | 400 | 14.94 |
| 12:08 ET | 992 | 14.945 |
| 12:10 ET | 776 | 14.93 |
| 12:12 ET | 500 | 14.93 |
| 12:14 ET | 584 | 14.93 |
| 12:15 ET | 1720 | 14.93 |
| 12:17 ET | 2451 | 14.93 |
| 12:19 ET | 1076 | 14.93 |
| 12:21 ET | 630 | 14.94 |
| 12:24 ET | 100 | 14.92 |
| 12:26 ET | 1500 | 14.91 |
| 12:28 ET | 731 | 14.91 |
| 12:30 ET | 806 | 14.935 |
| 12:32 ET | 300 | 14.92 |
| 12:33 ET | 300 | 14.91 |
| 12:35 ET | 500 | 14.91 |
| 12:37 ET | 400 | 14.91 |
| 12:39 ET | 900 | 14.9 |
| 12:42 ET | 2492 | 14.94 |
| 12:44 ET | 200 | 14.92 |
| 12:46 ET | 2905 | 14.94 |
| 12:48 ET | 1700 | 14.88 |
| 12:50 ET | 1348 | 14.93 |
| 12:51 ET | 100 | 14.935 |
| 12:53 ET | 300 | 14.955 |
| 12:55 ET | 800 | 14.94 |
| 12:57 ET | 500 | 14.93 |
| 01:00 ET | 1127 | 14.94 |
| 01:02 ET | 700 | 14.93 |
| 01:04 ET | 446 | 14.94 |
| 01:06 ET | 800 | 14.932 |
| 01:08 ET | 200 | 14.92 |
Yesterday
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12, from 8:00AM ET on Monday Nov 04, 2024 by Dow Jones
8:00AM ET on Monday Nov 04, 2024 by Dow Jones
Oct 31, 2024
DJ Avadel Pharmaceuticals Price Target Maintained With a $27.00/Share by HC Wainwright & Co., from 4:06PM ET on Thursday Oct 31, 2024 by Dow Jones
4:06PM ET on Thursday Oct 31, 2024 by Dow JonesDJ Avadel Pharmaceuticals Is Maintained at Outperform by Oppenheimer, from 2:31PM ET on Thursday Oct 31, 2024 by Dow Jones
2:31PM ET on Thursday Oct 31, 2024 by Dow JonesDJ Avadel Pharma Shares Rise on Favorable Ruling for FDA in Lumryz Litigation, from 11:14AM ET on Thursday Oct 31, 2024 by Dow Jones
11:14AM ET on Thursday Oct 31, 2024 by Dow JonesDJ Avadel Pharmaceuticals Price Target Maintained With a $22.00/Share by Needham, from 8:26AM ET on Thursday Oct 31, 2024 by Dow Jones
8:26AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Avadel Pharmaceuticals PLC | 1.4B | -12.8x | --- |
Phathom Pharmaceuticals Inc | 1.3B | -3.5x | --- |
Ocular Therapeutix Inc | 1.6B | -9.6x | --- |
Petro USA Inc | 1.0B | -31,250.0x | --- |
Liquidia Corp | 878.6M | -6.5x | --- |
Pliant Therapeutics Inc | 881.0M | -4.7x | --- |
Company Information
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Contact Information
- Headquarters
- Block 10-1 Blanchardstown Corporate Park BallycoolinDUBLIN, Ireland 15
- Phone
- ---
- Fax
- ---
Executives
- Independent Director
- Geoffrey Glass
- Chief Executive Officer, Director
- Gregory Divis
- Chief Financial Officer
- Thomas McHugh
- Chief Commercial Officer
- Richard Kim
- Independent Director
- Naseem Amin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
|---|---|
Revenue (TTM) | $95.1M |
Shares Outstanding | 96.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.43 |
EPS | $-1.17 |
Book Value | $0.98 |
P/E Ratio | -12.8x |
Price/Sales (TTM) | 15.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -103.82% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
